In CIS rats, XYS treatment, comparable to the JAK2 inhibitor AG490, alleviated anxiety-like behavior, reduced hippocampal damage, and inhibited activation of the TNF-α/JAK2-STAT3 pathway. Here, JAK2 is linked to in situ carcinoma.